New Agents and Insights from Basic Science

Faculty:

Pedro Cahn, MD, PhD Joseph J. Eron, Jr., MD Daniel R. Kuritzkes, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

• Recount data on the safety and efficacy of novel agents such as CCR5 inhibitors, entry inhibitors, and integrase inhibitors as therapy for treatment-experienced or treatment-naive HIV patients
• Summarize new data on the use of novel therapies in the setting of resistant HIV
• Describe the in vitro activity of novel therapies in the HIV setting, including novel PIs and fusion inhibitors

Topics covered include:

• Maraviroc in Patients With Dual/Mixed R5/X4 Virus
• Vicriviroc in R5-Tropic Treatment-Experienced Patients
• Virologic Benefit With Entry Inhibitor TNX-355 in Treatment-Experienced HIV-Infected Patients
• Novel PIs Demonstrate Potent in Vitro Activity Against Drug-Resistant HIV
• Fosalvudine Tidoxil Safe and Tolerable in Single-Dose Study in HIV-Infected Patients
• Integrase Inhibitor MK-0518 Shows Potent Activity in Treatment-Naive HIV-Infected Adults